27,830 results match your criteria myelodysplastic syndrome


Characteristics of macrophages from myelodysplastic syndrome microenvironment.

Exp Cell Res 2021 Sep 18:112837. Epub 2021 Sep 18.

Department of Hematology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China. Electronic address:

Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic neoplasms. The progression of malignancy is closely associated with immune regulation. Macrophages are indispensable tissue components and have been proposed to play a role in the pathophysiology of hematopoietic malignancies. Read More

View Article and Full-Text PDF
September 2021

U2af1 is a haplo-essential gene required for hematopoietic cancer cell survival in mice.

J Clin Invest 2021 Sep 21. Epub 2021 Sep 21.

Department of Medicine, Washington University School of Medicine, St. Louis, United States of America.

Somatic mutations in the spliceosome gene U2AF1 are common in patients with myelodysplastic syndromes. U2AF1 mutations that code for the most common amino acid substitutions are always heterozygous, and the retained wild-type allele is expressed, suggesting that mutant hematopoietic cells may require the residual wild-type allele to be viable. We show that hematopoiesis and RNA splicing in U2af1 heterozygous knock-out mice was similar to control mice, but that deletion of the wild-type allele in U2AF1(S34F) heterozygous mutant expressing hematopoietic cells (i. Read More

View Article and Full-Text PDF
September 2021

Myelodysplastic Syndromes: A New Decade.

Clin Lymphoma Myeloma Leuk 2021 Aug 2. Epub 2021 Aug 2.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL. Electronic address:

Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic stem cell disorders. The 2020 Surveillance, Epidemiology, and End Results data demonstrates the incidence rate of MDS increases with age especially in those greater than 70 years of age. Risk stratification that impact prognosis, survival, and rate of acute myeloid leukemia (AML) transformation in MDS is largely dependent on revised International Prognostic Scoring System along with molecular genetic testing as a supplement. Read More

View Article and Full-Text PDF

Functional polymorphisms of DNA repair genes in Latin America reinforces the heterogeneity of Myelodysplastic Syndrome.

Hematol Transfus Cell Ther 2021 Sep 9. Epub 2021 Sep 9.

Cancer Cytogenomic Laboratory, Universidade Federal do Ceara (UFC), Fortaleza, CE, Brazil; Post Graduate Program in Medical Science, Federal University of Ceara, Fortaleza, CE, Brazil. Electronic address:

Nucleotide excision repair pathway (NER) is an essential mechanism for single-strand breaks (SSB) repair while xeroderma pigmentosum family (XPA to XPG) is the most important system to NER. Myelodysplastic syndrome (MDS) is a heterogeneous hematological cancer characterized by cytopenias and risk of acute myeloid leukemia (AML) transformation. MDS pathogenesis has been associated with problems of DNA repair system. Read More

View Article and Full-Text PDF
September 2021

Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders.

Br J Haematol 2021 Sep 20. Epub 2021 Sep 20.

Immunology Service, Clinic University Hospital Virgen de la Arrrixaca (HCUVA), Murcia, Spain.

Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB) deficiency is present in ˜0·05% of the general population. Among our patients, FcγRIIIB deficiency was less frequent in those with immune-system disorders (one of 1815 patients, 0·05%) than in those with blood disorders (nine of 2147 patients, 0·42%, P = 0·023): mainly primary immune thrombocytopenia (4·34%), therapy related myeloid neoplasms (1·16%) and myelodysplastic syndrome with excess blasts (1·28%). Four of the nine (44·4%) patients with blood disorders were diagnosed with or quickly evolved to acute myeloid leukaemia (AML), suggesting that FcγRIIIB deficiency could be an adverse prognostic factor for progression to AML that should be confirmed in large multicentre studies. Read More

View Article and Full-Text PDF
September 2021

Flow Cytometric Findings in Clonal Cytopenia of Undetermined Significance.

Am J Clin Pathol 2021 Sep 20. Epub 2021 Sep 20.

Department of Pathology, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH, USA.

Objectives: To examine flow cytometric (FCM) findings in clonal cytopenia of undetermined significance (CCUS) in relation to variant allele fraction (VAF) and mutation risk.

Methods: Nine FCM parameters, including 5 FCM metrics (Meyerson-Alayed scoring scheme [MASS] parameters) we previously used to identify myelodysplastic syndromes (MDS), were compared among 96 CCUS samples, 100 low-grade MDS samples and 100 samples from patients without somatic alterations (controls).

Results: FCM findings did not differ between CCUS samples with less than 20% VAF and controls. Read More

View Article and Full-Text PDF
September 2021

Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.

Am J Blood Res 2021 15;11(4):417-426. Epub 2021 Aug 15.

Clinica di Ematologia-Università Politecnica delle Marche e A.O.U. Ospedali Riuniti di Ancona Italy.

TP53 gene mutations are common in Myelodysplastic Syndromes (MDS) with del5q and have a clinical and prognostic significance. Next Generation Sequencing (NGS) is an accurate, but expensive, technique, and not commonly available. Immunohistochemistry (IHC) for TP53 expression has been recently used as a surrogate to assess TP53 mutations. Read More

View Article and Full-Text PDF

Gene mutation spectrum of patients with myelodysplastic syndrome and progression to acute myeloid leukemia.

Int J Hematol Oncol 2021 Jun 22;10(2):IJH34. Epub 2021 Jun 22.

Division of Pathology & Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang 065201, China.

Aim: This study aimed to investigate the regularity of gene mutations in patients with myelodysplastic syndrome (MDS) and in those that progressed to acute myeloid leukemia (MDS/AML).

Patients & Methods: High-throughput sequencing technology was used to detect gene mutations in 99 newly diagnosed patients with MDS or MDS/AML.

Results: Gene mutations were detected in 88 patients. Read More

View Article and Full-Text PDF

Bone Marrow versus Peripheral Blood Graft for Haploidentical HCT with Post Transplantation Cyclophosphamide.

Transplant Cell Ther 2021 Sep 16. Epub 2021 Sep 16.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

Background: In the COVID-19 pandemic era, the numbers of haploidentical hematopoietic cell transplantation (HCT) with peripheral blood (PB) versus bone marrow (BM) grafts increased significantly, which may be associated with adverse outcomes.

Methods: We compared outcomes of BM vs PB grafts in patients ≥18 years with hematological malignancy who underwent T-cell replete haploidentical HCT and graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide, tacrolimus and mycophenolate mofetil.

Findings: Of 264 patients, 180 (68%) received BM and 84 (32%) received PB graft. Read More

View Article and Full-Text PDF
September 2021

Detecting attomolar concentrations of microRNA related to myelodysplastic syndromes in blood plasma using a novel sandwich assay with nanoparticle release.

Biosens Bioelectron 2021 Sep 3;194:113613. Epub 2021 Sep 3.

Institute of Photonics and Electronics of the Czech Academy of Sciences, Chaberská 1014/57, 182 51 Prague, Czech Republic. Electronic address:

Microribonucleic acids (miRNAs) are short noncoding ribonucleic acids that have been linked with a multitude of human diseases including lung, breast, and hematological cancers. In this work, we present a novel, extremely sensitive assay for the label-free optical biosensor-based detection of miRNAs, which is based on the oligonucleotide-triggered release of nanoparticles from a sensor surface. We combine this assay (herein referred to as the nanoparticle-release (NPR) assay) with a surface plasmon resonance biosensor and show that the assay is able to enhance the specific sensor response associated with the binding of target miRNA while suppressing the interfering effects caused by the non-specific binding. Read More

View Article and Full-Text PDF
September 2021

Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome.

Br J Haematol 2021 Sep 18. Epub 2021 Sep 18.

Division of Haematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Increasing evidence supports the role of the immune microenvironment and associated signalling in the pathogenesis of myelodysplastic syndromes (MDS). Nevertheless, the clinical relevancy of immune signals in patients with MDS remains elusive. To address this, we used single-sample gene-set enrichment analysis to score immune signatures of bone marrow (BM) samples from 176 patients with primary MDS. Read More

View Article and Full-Text PDF
September 2021

ASXL1 and STAG2 are Common Mutations in GATA2 Deficiency Patients with Bone Marrow Disease and Myelodysplastic Syndrome.

Blood Adv 2021 Sep 16. Epub 2021 Sep 16.

National Insitutes of Health, Bethesda, Maryland, United States.

GATA2 Deficiency patients harbor de novo or inherited germline mutations in the GATA2 transcription factor gene, predisposing them to myeloid malignancies. There is considerable variation in disease progression, even among family members with the same mutation in GATA2. We investigated somatic mutations in 106 patients with GATA2 Deficiency to identify acquired mutations that are associated with myeloid malignancies. Read More

View Article and Full-Text PDF
September 2021

Poly (ADP-ribose) polymerase-1 (PARP1) as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Blood Adv 2021 Sep 16. Epub 2021 Sep 16.

University of Athens, Athens, Greece.

Poly (ADP-ribose) polymerase-1 (PARP1) is a key mediator of various forms of DNA damage repair and plays an important role in the progression of several cancer types. The enzyme is activated by binding to DNA single-strand and double-strand breaks. Its contribution to chromatin remodeling makes PARP1 crucial for gene expression regulation. Read More

View Article and Full-Text PDF
September 2021

Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.

J Cancer Res Clin Oncol 2021 Sep 16. Epub 2021 Sep 16.

Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.

Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an extremely rare disease that originates from dendritic cells and is associated with a poor overall survival (OS). Diagnostic and therapeutic standards are less well-established in comparison to other leukemic conditions and standards of care are lacking. Morphologic and molecular similarities to acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are hard to distinguish. Read More

View Article and Full-Text PDF
September 2021

Portable Medical Orders and End of Life Measures in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Blood Adv 2021 Sep 15. Epub 2021 Sep 15.

University of Rochester Medical Center, Rochester, New York, United States.

Patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) experience high rates of hospitalization, intensive care unit (ICU) admissions, and in-hospital deaths at end of life (EOL). Early goals-of-care (GOC) discussions might reduce intensity of care at EOL. Portable Medical Order (POLST) forms, known as Medical Orders for Life Sustaining Treatment (MOLST) forms in New York State, allow patients to translate GOC discussions into specific medical orders that communicate their wishes during a medical emergency. Read More

View Article and Full-Text PDF
September 2021

Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation.

Int J Hematol 2021 Sep 14. Epub 2021 Sep 14.

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.

The efficacy of pharmacokinetically (PK) guided, once-daily administration of busulfan (BU) was evaluated in elderly patients with acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Twenty-one patients (median age 61) received 30 mg/m fludarabine for 6 days and BU for 4 days, starting from 3.2 mg/m and subsequently adjusted to the target area under the curve (AUC) of 6000 µmol-min/L. Read More

View Article and Full-Text PDF
September 2021

Tissue-specific telomere shortening and degenerative changes in a patient with mutation and dyskeratosis congenita.

Hum Pathol (N Y) 2021 Sep 5;25. Epub 2021 Jul 5.

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, United States.

Dyskeratosis congenita is a disease of impaired tissue maintenance downstream of telomere dysfunction. Characteristically, patients present with the clinical triad of nail dystrophy, oral leukoplakia, and skin pigmentation defects, but the disease involves degenerative changes in multiple organs. Mutations in telomere-binding proteins such as TINF2 (TRF1-interacting nuclear factor 2) or in telomerase, the enzyme that counteracts age related telomere shortening, are causative in dyskeratosis congenita. Read More

View Article and Full-Text PDF
September 2021

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.

Blood Cancer J 2021 09 14;11(9):151. Epub 2021 Sep 14.

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphoproliferative disorders (CLD), multiple myeloma (MM), or myelodysplastic/myeloproliferative syndromes (MDS/MPN). Antibody (Ab) levels to the SARS-CoV-2 nucleocapsid (N) and spike (S) protein were measured at +1, +3, +6 months after nasal swabs became PCR-negative. Read More

View Article and Full-Text PDF
September 2021

Therapeutic targeting of the inflammasome in myeloid malignancies.

Blood Cancer J 2021 Sep 14;11(9):152. Epub 2021 Sep 14.

Division of Hemato-Oncology, Department of Oncology, Albert Einstein College of Medicine, Bronx, NY, USA.

Even though genetic perturbations and mutations are important for the development of myeloid malignancies, the effects of an inflammatory microenvironment are a critical modulator of carcinogenesis. Activation of the innate immune system through various ligands and signaling pathways is an important driver of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The DAMPs, or alarmins, which activate the inflammasome pathway via the TLR4/NLR signaling cascade causes the lytic cell death of hematopoietic stem and progenitor cells (HSPCs), ineffective hematopoiesis, and β-catenin-induced proliferation of cancer cells, leading to the development of MDS/AML phenotype. Read More

View Article and Full-Text PDF
September 2021

Successful treatment of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa after allogeneic hematopoietic stem cell transplantation with colistin and amikacin inhalation therapy.

J Infect Chemother 2021 Sep 10. Epub 2021 Sep 10.

Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, Japan. Electronic address:

Pseudomonas aeruginosa is a Gram-negative bacillus that often causes severe infections during immunosuppression in patients with hematologic malignancies. P. aeruginosa can easily acquire drug resistance, and often develops into multidrug-resistant P. Read More

View Article and Full-Text PDF
September 2021

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.

Br J Haematol 2021 Sep 12. Epub 2021 Sep 12.

CHU de Lille, INSERM U1286, Univ Lille, Lille, France.

Allogeneic haematopoietic-cell transplantation (allo-HCT) is a potentially curative therapy for high-risk myelodysplastic syndrome (MDS). Reduced-intensity conditioning (RIC) is usually associated with lower non-relapse mortality (NRM), higher relapse rate and similar overall-survival (OS) as myeloablative-conditioning (MAC). Fludarabine/treosulfan (FT) is a reduced-toxicity regimen with intense anti-leukaemia activity and a favourable toxicity profile. Read More

View Article and Full-Text PDF
September 2021

Higher-risk myelodysplastic syndrome in an elderly patient: Long-term partial remission with low-dose prednisone, G-CSF, and epoetin alfa.

Authors:
Anwarul Islam

Clin Case Rep 2021 Sep 7;9(9):e04752. Epub 2021 Sep 7.

Division of Hematology/Oncology Department of Medicine Buffalo General Medical Center Buffalo New York USA.

Currently, most patients with higher-risk MDS are treated with 5-azacitidine or decitabine. These agents are toxic. The treatment described here is safe, devoid of toxicity, fosters improved quality of life, and helps reduce transfusion requirements. Read More

View Article and Full-Text PDF
September 2021

Secondary primary malignancies in patients with multiple myeloma: A single institution experience.

Hematol Oncol 2021 Sep 12. Epub 2021 Sep 12.

Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.

The purpose of our study is to highlight the demographic characteristics, pathological features, and clinical course of multiple myeloma (MM) patients with secondary primary malignancies (SPM). A retrospective chart review was performed from January 2009 to February 2020. Patients' demographic, pathologic and cytogenetic features, treatment characteristics and clinical outcomes were collected. Read More

View Article and Full-Text PDF
September 2021

Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pediatric myelodysplastic syndrome.

Bone Marrow Transplant 2021 Sep 10. Epub 2021 Sep 10.

Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Aichi, Japan.

Cytogenetic abnormalities are a major risk factor for relapse after hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS). We aimed to evaluate the value of the five-group cytogenetic classification according to the revised International Prognostic Scoring System (R-IPSS) for predicting the outcome after HSCT in pediatric patients with MDS. We retrospectively analyzed the Japanese registration data of 242 pediatric patients with MDS. Read More

View Article and Full-Text PDF
September 2021

The Myeloid-Kidney Interface in Health and Disease.

Clin J Am Soc Nephrol 2021 Sep 10. Epub 2021 Sep 10.

M Rauh, Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada.

Kidney homeostasis is highly dependent upon the correct functioning of myeloid cells. These cells form a distributed surveillance network throughout the kidney, where they play an integral role in the response to organ threat. Dysregulation of resident pro-inflammatory and pro-fibrotic macrophages leads to kidney structural damage and scarring following kidney injury. Read More

View Article and Full-Text PDF
September 2021

Planned granulocyte-colony stimulating factor adversely impacts survival after allogeneic hematopoietic cell transplantation performed with Thymoglobulin for myeloid malignancy.

Transplant Cell Ther 2021 Sep 7. Epub 2021 Sep 7.

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Background: The in vivo depletion of recipient and donor T-lymphocytes using anti-thymocyte globulin (ATG) is widely adopted in allogeneic hematopoietic stem cell transplantation (HCT) to reduce the incidence of both graft failure and graft versus host disease (GVHD). However excess toxicity to donor lymphocytes may hamper immune reconstitution, compromising anti-tumour effects and increasing infection. Granulocyte-colony stimulating factor (G-CSF) administered early after HCT may increase ATG-mediated lympho-toxicity. Read More

View Article and Full-Text PDF
September 2021

Herlyn Werner Wunderlich Syndrome Presenting with Ischemic Stroke due to Suspected Paroxysmal Nocturnal Hemoglobinuria: A Case Report.

JNMA J Nepal Med Assoc 2021 Feb 28;59(234):192-196. Epub 2021 Feb 28.

Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal.

Paroxysmal nocturnal hemoglobinuria can rarely present as cerebral ischemia and stroke due to arterial thrombosis. However, it should be considered in a young patient with bone marrow failure features, systemic thromboses, and hemolysis. The variants of paroxysmal nocturnal hemoglobinuria pose a diagnostic challenge and hence are important to recognize. Read More

View Article and Full-Text PDF
February 2021

The cell body space occupied by the nucleus during the cell differentiation in human lymphocytic, granulocytic and erythroid cell lineages.

Physiol Res 2021 Sep 10. Epub 2021 Sep 10.

Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic.

The present nuclear and cell body diameter measurements demonstrated size differences of the approximate cell space estimate occupied by the cell nucleus during the cell differentiation in lymphocytic, granulocytic and erythroid cell lineages. These lineages were used as convenient models because all differentiation steps were easily identified and accessible in diagnostic peripheral blood or bone marrow smears of blood donors (BDs), patients suffering from chronic lymphocytic leukemia (CLL), patients with chronic myeloid leukemia (CML) and refractory anemia (RA) of the myelodysplastic syndrome (MDS). The cell space occupied by the nucleus was constant and did not change during the cell differentiation in the lymphocytic cell lineages of BDs and CLL patients despite the decreased cell size. Read More

View Article and Full-Text PDF
September 2021